Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Blood-Brain Barrier Modeled with Multicellular Spheroids

The blood–brain barrier (BBB) is conservative, standing athwart the brain’s blood supply yelling “stop” at harmful chemicals and invaders the rest of the body is inclined to welcome. Although the BBB performs an essential gatekeeping function, accepting innocu

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The blood–brain barrier (BBB) is conservative, standing athwart the brain’s blood supply yelling “stop” at harmful chemicals and invaders the rest of the body is inclined to welcome. Although the BBB performs an essential gatekeeping function, accepting innocuous nutrients and rejecting potentially dangerous substances, it can try the patience of drug developers, who struggle to design blood-borne neuroactive therapeutics that can actually reach the brain.

To keep the BBB from frustrating progress against diseases of the central nervous system, researchers based at Brigham and Women’s Hospital (BWH) have looked beyond traditional approaches to the screening of brain-penetrating drugs. These approaches include animal models and cell cultures. Unfortunately, animal models are expensive and laborious and can only be used to test a limited number of compounds at a time. And cell cultures often fail to replicate the conditions found in the human body. For example, in typical cultures, cells are grown on flat plastic surfaces and isolated by cell type. They may become less and less like the unique cells found in the brain over time.

Brain tissue section showing accumulation of a blood–brain barrier-penetrating peptide (in white) in the brain tissue (outside of blood vessels). A green dye is used to highlight the blood vessels within the animal, and cell nuclei are represented in blue. [Choi-Fong Cho/BWH]

Demonstrating an openness to new approaches, the BWH team has developed an innovative but easily implemented approach that uses “spheroids” to mimic the BBB more accurately. These spheroids appear to overcome several challenges for discovering and advancing new drugs for treating brain conditions.

Details appeared June 6 in the journal Nature Communications, in an article entitled “Blood-Brain-Barrier Spheroids as an In Vitro Screening Platform for Brain-Penetrating Agents.” This article describes how different kinds of brain cells—endothelial cells, pericytes, and astrocytes—can be grown together so that they spontaneously form multicellular spheroids. Astrocytes form the core of the spheroids, whereas endothelial cells and pericytes encase the surface, acting as a barrier that regulates transport of molecules.

“The spheroid surface exhibits high expression of tight junction proteins, VEGF [vascular endothelial growth factor]-dependent permeability, efflux pump activity, and receptor-mediated transcytosis of angiopep-2,” report the article’s authors. “In contrast, the transwell co-culture system displays comparatively low levels of BBB regulatory proteins, and is unable to discriminate between the transport of angiopep-2 and a control peptide.”

These self-assembled structures closely resemble the BBB organization and can be used to predict drug penetration capabilities—molecules that can penetrate the surface of the spheres and accumulate inside are more likely to be able to penetrate the BBB and enter the brain in a living organism.

“Our model takes a new approach to mimic the BBB outside of a living system. These miniature spheroids are relatively straightforward to culture, and yet it is able to reproduce many of the key BBB properties and functions,” said lead author Choi-Fong Cho, Ph.D. “Our hope is that these findings will further advance neuroscience research and expedite the discovery and design of brain-penetrant drugs to treat diseases of the brain and central nervous system.”

The research team performed several tests on these spheroids to establish some of the key properties of the BBB that allow it to restrict the influx of foreign molecules. The spheroid model scored much better on many of these properties than the standard model in use today. The team also used the spheroids to identify new brain-penetrant molecules, which could hold high potential for delivering therapeutics across the BBB.

“We plan to use this model going forward in our own research to identify new therapeutics for glioblastoma,” said senior author Sean Lawler, Ph.D. “This is a very versatile model and should allow our group and others to test not only molecules but also viruses, cells and more that may be able to cross the BBB”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →